Inventor
ICHIM THOMAS E
US15 patents
⚠️ This page may combine multiple inventors who share the name “ICHIM THOMAS E”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ICHIM THOMAS E
4 patentsUS11266707B2Mar 8, 2022
Nutraceuticals for the prevention, inhibition, and treatment of SARS-CoV-2 and associated COVID-19
ICHIM THOMAS E8 citations82
US8241621B2Aug 14, 2012
Stem cell mediated treg activation/expansion for therapeutic immune modulation
ICHIM THOMAS E7 citations82
US11229674B1Jan 25, 2022
Nutraceuticals for suppressing indolamine 2,3 deoxygenase
ICHIM THOMAS E7 citations81
US9598673B2Mar 21, 2017
Treatment of disc degenerative disease
ICHIM THOMAS E6 citations71
THERAPEUTIC SOLUTIONS INT INC
4 patentsUS11504410B2Nov 22, 2022
Neuroprotection and neuroregeneration by pterostilbene and compositions thereof
THERAPEUTIC SOLUTIONS INT INC2 citations68
US12011462B2Jun 18, 2024
Stimulation of mesenchymal stem cell therapeutic activities by T regulatory cells
THERAPEUTIC SOLUTIONS INT INC0 citations55
US11957727B2Apr 16, 2024
Prevention of neuroinflammation associated memory loss using nutraceutical compositions
THERAPEUTIC SOLUTIONS INT INC0 citations55
US11759495B2Sep 19, 2023
Upregulation of therapeutic T regulatory cells and suppression of suicidal ideations in response to inflammation by administration of nutraceutical compositions alone or combined with minocycline
THERAPEUTIC SOLUTIONS INT INC1 citations55
MYELOID THERAPEUTICS INC
3 patentsUS11918605B1Mar 5, 2024
Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
MYELOID THERAPEUTICS INC6 citations82
US11517589B2Dec 6, 2022
Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
MYELOID THERAPEUTICS INC9 citations82
US11918604B2Mar 5, 2024
Chimeric antigen receptor dendritic cell (CAR-DC) for treatment of cancer
MYELOID THERAPEUTICS INC3 citations71